Intervet/Schering-Plough Animal Health shows innovative portfolio at WSAVA congress, Dublin - Hubert Trentesaux appointed as head of Global Companion Animal
20 August 2008
BOXMEER (the Netherlands), August 20, 2008 – At the 33rd annual World Small Animal Veterinary Association Congress (WSAVA) in Dublin, Ireland, August 20-24, Intervet/Schering-Plough Animal Health, presents a comprehensive range of solutions in all key market segments, including vaccines, pharmaceuticals, and innovative companion animal programs for veterinary professionals.
At the WSAVA congress for small animal veterinarians, Intervet/Schering-Plough Animal Health sponsors key scientific lectures on dermatology, supporting its global leadership with its first and second generation otic preparations for acute and chronic otitis externa- OTOMAX® and MOMETAMAX®. The company also sponsors a cardiorespiratory lecture on VASOTOP®, one of the most potent long-acting angiotensin converting enzyme (ACE) inhibitors. Also being highlighted are CANINSULIN/VETSULIN®, veterinary insulin for the treatment of diabetes mellitus in dogs and cats and NOBIVAC®/GALAXY® and ECLIPSE®, the main vaccine lines for the immunization of cats and dogs against infectious diseases.
The congress also serves as the venue for the presentation of the WSAVA Intervet/Schering-Plough Animal Health international award for service to the professional. The award will be granted to a leading veterinary professional.
Hubert Trentesaux, recently appointed as Head of Global Companion Animal at Intervet/Schering-Plough Animal Health, said: "Our companion animal activities aim to improve the length and quality of the lives of pets and foster the human-animal bond. As the world market leader in the production of animal health vaccines, our goal is to develop innovative vaccines that address unmet needs and improve disease protection, as well as the duration of that protection. “
In the specialty pharmaceutical area, Intervet/Schering-Plough Animal Health targets complex diseases such as diabetes and cardiovascular disease. Trentesaux: “Our approach in the companion animal market is to partner with veterinary professionals and to provide useful and innovative value programs, such as CHILLER UNITS, a device for storing and dispensing vaccines, HomeAgain®, a pet recovery system and MyVetOnLine®, an online tool offering clinics a dynamic website as well as in-clinic educational tools.”
Hubert Trentesaux is responsible for marketing strategies in the global and regional companion animal markets. He served as Vice President, Global Companion Animal at Schering-Plough Animal Health, since 2003. He joined the company in 1984 as a Marketing Planning Manager in France and held various positions of increasing responsibility. In 1988 he was appointed Marketing Director in France and in 1991 he became General Manager, Spain, Animal Health. Trentesaux returned to France in 1997 as General Manager, France, Animal Health and in 2001 he was appointed Vice President, U.S. Companion Animal. In 2003, he was appointed Vice President, Global Companion Animal. Hubert Trentesaux holds a MBA degree in International Agri-Food Management and a master’s degree in Agriculture.
The new combination Intervet/Schering-Plough Animal Health strengthens the animal health portfolio in several areas and brings together complementary lines of vaccines, pharmaceuticals, parasiticides and an enhanced science and technology platform. This ensures on-going commitment to meeting the challenges of the various species segments. Intervet/Schering-Plough Animal Health is not only the world market leader in the production of animal health vaccines, but is also one of the world’s leaders in the field of animal health.
###
Note for the editor
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its website is www.schering-plough.com.
Intervet/Schering-Plough Animal Health is focusing on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative Animal Health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. For more information about Intervet/Schering-Plough Animal Health visit the following website: www.intervet.com
